Multimodal multifocal confocal Raman and phase microscopy with enhanced resolution

项目总结 TRD3：拉曼光谱和成像 调查人员：R.R.达萨里(3.1)[联席牵头]；I.巴曼(3.2)；C.L.埃文斯(3.3)[联席牵头] 拉曼技术提供了检测、量化和可视化分子物种的能力，具有高灵敏度和 通过其独特的振动指纹实现高分辨率，使一系列生物医学应用得以实现 把板凳放到床边。LBRC在拉曼技术开发方面一直处于领先地位，其贡献包括 AS：血糖传感工具包、化学计量学算法和临床拉曼光谱系统。在这 下一个周期，LBRC将在三个令人兴奋的领域推动技术：开发高速多式联运 增强分辨率的共聚焦拉曼和位相显微镜增强细胞力学生物学研究 (目标3.1)，开发探测细胞纳米力学和伴随而来的生物的技术 响应(目标3.2)，并开发一种便携式、强大的临床相干拉曼成像系统 活体评估黑色素瘤和其他皮肤疾病(目标3.3)。与加藤博士的合作 利用长期拉曼成像技术研究镰状红细胞老化对其机械性能的影响 用于量化细胞年龄的血糖标志物和用于量化细胞力学的膜波动时相成像 (CP2)。与拉曼博士的合作旨在剖析转移性乳腺癌中器官特异性差异。 通过测定微环境诱导的生物物理和分子适应(CP5)。这种协作性 努力将提供对转移器官趋向性的机械性见解，这是发现最佳转移器官的关键一步 针对特定转移灶的治疗策略，以提高总体存活率。正在进行的协作项目 费舍尔博士将把目前关于天然色素苯红色素致癌性质的发现转化为 动物模型到人类的研究主要集中在无色素性黑色素瘤(CP6)的识别和治疗上。

PROJECT SUMMARY TRD 3: RAMAN SPECTROSCOPY AND IMAGING Investigators: R.R. Dasari (3.1) [co-lead]; I. Barman (3.2); C.L. Evans (3.3) [co-lead] Raman technologies offer the ability to detect, quantify, and visualize molecular species with high sensitivity and high resolution via their unique vibrational fingerprints, enabling a host of biomedical applications ranging from bench to the bedside. The LBRC has been a leader in Raman technology development with contributions such as: blood glucose sensing toolkits, chemometric algorithms, and clinical Raman spectroscopy systems. In this next cycle, the LBRC pushes technologies in three exciting areas: developing a high-speed multimodal confocal Raman and phase microscopy with enhanced resolution to enhance cellular mechanobiology studies (Aim 3.1), developing technologies for probing cellular nanomechanics and the accompanying biological responses (Aim 3.2), and developing a portable, robust clinical coherent Raman imaging system for the assessment of melanoma and other diseases of the skin in vivo (Aim 3.3). The collaboration with Dr. Kato investigates how sickle red cells aging affects their mechanical properties using Raman imaging of long term glycemic markers to quantify cell age and phase imaging of membrane fluctuations to quantify cell mechanics (CP2). The collaboration with Dr. Raman seeks to dissect organ-specific differences in metastatic breast cancer by determining microenvironment induced biophysical and molecular adaptations (CP5). This collaborative effort will offer mechanistic insights into metastasis organotropism, a critical step towards discovering optimal treatment strategies for specific metastatic lesions to improve overall survival. The ongoing collaborative project with Dr. Fisher will translate current findings on the oncogenic nature of the natural pigment pheomelanin in animal models to human studies focused on the identification and therapy of amelanotic melanomas (CP6).